Shandong Lukang Pharmaceutical Co.,Ltd. (SHA:600789)
China · Delayed Price · Currency is CNY 9.19
+0.11 (1.21%)
At close: Feb 3, 2026
SHA:600789 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 6,122 | 6,164 | 6,067 | 5,545 | 4,877 | 4,143 |
Other Revenue | 68.85 | 68.85 | 79.76 | 76.51 | 47.22 | 61.88 |
| 6,190 | 6,233 | 6,147 | 5,621 | 4,924 | 4,205 | |
Revenue Growth (YoY) | 1.79% | 1.41% | 9.34% | 14.17% | 17.09% | 12.65% |
Cost of Revenue | 4,778 | 4,806 | 4,686 | 4,416 | 3,777 | 3,247 |
Gross Profit | 1,413 | 1,427 | 1,461 | 1,206 | 1,147 | 958.25 |
Selling, General & Admin | 720.24 | 802.19 | 810.21 | 688.02 | 675.05 | 619.33 |
Research & Development | 314.87 | 317.15 | 345.79 | 264 | 266.03 | 192.63 |
Other Operating Expenses | 40.37 | -11.81 | 37.65 | 51.16 | 38.04 | 27.16 |
Operating Expenses | 1,079 | 1,110 | 1,195 | 1,012 | 1,004 | 847.25 |
Operating Income | 333.18 | 316.74 | 266.14 | 194.06 | 143.37 | 111.01 |
Interest Expense | -67.48 | -75.38 | -79.17 | -98.04 | -65.13 | -63.35 |
Interest & Investment Income | 10.96 | 12.48 | 8.94 | 7.19 | 6.92 | 11.57 |
Currency Exchange Gain (Loss) | 11.93 | 11.93 | 7.52 | 19.49 | -5.52 | -11.19 |
Other Non Operating Income (Expenses) | -12.65 | -13.8 | -7.22 | -5.85 | -4.63 | -2.27 |
EBT Excluding Unusual Items | 275.94 | 251.97 | 196.2 | 116.85 | 75.02 | 45.77 |
Gain (Loss) on Sale of Investments | -4.88 | -7.56 | -7.2 | -6.53 | -3.18 | -0.06 |
Gain (Loss) on Sale of Assets | -2.44 | 153.42 | 0.28 | 2.65 | -0.38 | 201.03 |
Asset Writedown | -52.95 | -0.15 | - | -0.82 | -0.14 | -0.15 |
Other Unusual Items | 32.24 | 36.22 | 83.7 | 37.95 | 42.27 | 15.57 |
Pretax Income | 247.91 | 433.9 | 272.98 | 150.1 | 113.58 | 262.16 |
Income Tax Expense | 49.86 | 25.55 | 16.19 | 6.98 | 23.69 | 28.68 |
Earnings From Continuing Operations | 198.05 | 408.35 | 256.79 | 143.11 | 89.89 | 233.48 |
Minority Interest in Earnings | -9.29 | -13.73 | -10.62 | -5.1 | -0.79 | -5.61 |
Net Income | 188.75 | 394.62 | 246.17 | 138.01 | 89.1 | 227.88 |
Net Income to Common | 188.75 | 394.62 | 246.17 | 138.01 | 89.1 | 227.88 |
Net Income Growth | -52.89% | 60.30% | 78.37% | 54.90% | -60.90% | 87.94% |
Shares Outstanding (Basic) | 891 | 897 | 879 | 863 | 891 | 876 |
Shares Outstanding (Diluted) | 891 | 897 | 879 | 920 | 891 | 912 |
Shares Change (YoY) | 0.13% | 2.01% | -4.45% | 3.27% | -2.25% | 5.24% |
EPS (Basic) | 0.21 | 0.44 | 0.28 | 0.16 | 0.10 | 0.26 |
EPS (Diluted) | 0.21 | 0.44 | 0.28 | 0.15 | 0.10 | 0.25 |
EPS Growth | -52.95% | 57.14% | 86.67% | 50.00% | -60.00% | 78.57% |
Free Cash Flow | -20.23 | 123.64 | 266.09 | 16.02 | -311.07 | -468.57 |
Free Cash Flow Per Share | -0.02 | 0.14 | 0.30 | 0.02 | -0.35 | -0.51 |
Dividend Per Share | 0.112 | 0.132 | 0.090 | 0.050 | 0.050 | 0.055 |
Dividend Growth | 1.82% | 46.67% | 80.00% | - | -9.09% | 22.22% |
Gross Margin | 22.82% | 22.89% | 23.77% | 21.45% | 23.29% | 22.79% |
Operating Margin | 5.38% | 5.08% | 4.33% | 3.45% | 2.91% | 2.64% |
Profit Margin | 3.05% | 6.33% | 4.00% | 2.46% | 1.81% | 5.42% |
Free Cash Flow Margin | -0.33% | 1.98% | 4.33% | 0.29% | -6.32% | -11.14% |
EBITDA | 745.61 | 715.75 | 647.27 | 542.18 | 450.83 | 354.94 |
EBITDA Margin | 12.04% | 11.48% | 10.53% | 9.64% | 9.16% | 8.44% |
D&A For EBITDA | 412.43 | 399.01 | 381.13 | 348.12 | 307.46 | 243.93 |
EBIT | 333.18 | 316.74 | 266.14 | 194.06 | 143.37 | 111.01 |
EBIT Margin | 5.38% | 5.08% | 4.33% | 3.45% | 2.91% | 2.64% |
Effective Tax Rate | 20.11% | 5.89% | 5.93% | 4.65% | 20.86% | 10.94% |
Revenue as Reported | 6,190 | 6,233 | 6,147 | 5,621 | 4,924 | 4,205 |
Advertising Expenses | - | - | - | - | 259.79 | 59.76 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.